Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Conditions:   Pancreatic Ductal Adenocarcinoma;   Locally Advanced Cancer;   Metastatic Cancer Interventions:   Drug: FOLFIRI;   Drug: OSE2101;   Drug: Nivolumab Sponsors:   GERCOR - Multidisciplinary Oncology Cooperative Group;   OSE Immunotherapeutics;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials